3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other hematologic neoplasm
1
Conditions
Leukemia, Promyelocytic, Acute
3
Thrombocytopenia
2
Pathologic Complete Response
2
Uterine Cervical Neoplasms
1
Pancreatic Neoplasms
1
Ovarian Neoplasms
1
Oropharyngeal Neoplasms
1
Neoplasms
1
Multiple Myeloma
1
Lung Neoplasms
1
Leukemia
1
Laryngeal Neoplasms
1
Hypopharyngeal Neoplasms
1
Hematologic Neoplasms
1
Hematologic Diseases
1
Head and Neck Neoplasms
1
Gastrointestinal Neoplasms
1
Fallopian Tube Neoplasms
1
Endometrial Neoplasms
1
Digestive System Neoplasms
1
Colorectal Neoplasms
1
Carcinoma, Non-Small-Cell Lung
1
Breast Neoplasms
1
Interventions
Cyclophosphamide
16
fludarabine
9
Mycophenolic Acid
8
Cytarabine
8
venetoclax
7
Busulfan
7
fludarabine phosphate
6
Whole-Body Irradiation
6
Tacrolimus
5
Cyclosporine
5
ruxolitinib
4
ponatinib
4
Rituximab
4
Peripheral Blood Stem Cell Transplantation
4
Methotrexate
4
Etoposide
4
Daunorubicin
4
blinatumomab
3
asciminib
3
Vincristine
3
Prednisone
3
Mercaptopurine
3
Inotuzumab Ozogamicin
3
Dexamethasone
3
revumenib
2
pegfilgrastim
2
nilotinib
2
ibrutinib
2
Mesna
2
Melphalan
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Leukemia
×
Tretinoin
×
90 days
×
Clear all
NCT07504458
2026-04-16
QUATRO-APL
Quetzal Therapeutics
Phase 3
Recruiting
150 enrolled